RecruitingNCT04902807
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment
500 participants
Start Date
Sep 7, 2021
Study Type
OBSERVATIONAL
Conditions
Autoimmune HepatitisSystemic Lupus ErythematosusHemophagocytic LymphohistiocytosesAutoimmune DiseasesAutoimmune DiabetesAutoimmune Lymphoproliferative SyndromeAutoimmune CytopeniaAutoimmune AnemiaAutoimmune ThrombocytopeniaAutoimmune Rheumatologic DiseaseJuvenile Idiopathic ArthritisEBV LymphoproliferationRAS-Associated Autoimmune Leucoproliferative DiseasePrimary ImmunodeficiencyAPECEDIPEXBENTAEnteropathy, AutoimmuneCombined ImmunodeficiencyIBD
Summary
The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).
Eligibility
Min Age: 1 YearMax Age: 18 Years
Inclusion Criteria8
- Individuals aged\<18 y/o.
- Individuals \> 6 kg
- Individuals not affected by an immune-related disease or not affected by cancer
- Individuals whose parents have signed an enlightened consent.
- Individuals with health insurance.
- Individuals aged\<18 y/o.
- Individuals \> 9 kg
- Patients whose parents have signed an enlightened consent.
Exclusion Criteria6
- Intake of antibiotics within 2 weeks prior inclusion
- Absence of parent's or child consent form
- Cytotoxic cancer treatments
- antiviral treatments (HIV, hepatitis …)
- Short term life-threatening conditions
- Individuals placed under judicial protection
Interventions
BIOLOGICALCollection of samples
Blood, Urine and Stool samples will be collected from the participants.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04902807
Related Trials
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT0691680633 locations
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
NCT073714683 locations
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease
NCT073005531 location
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT073635903 locations